Real-world Data for Clinical Evidence Generation in Oncology
Top Cited Papers
Open Access
- 13 September 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 109 (11)
- https://doi.org/10.1093/jnci/djx187
Abstract
Conventional cancer clinical trials can be slow and costly, often produce results with limited external validity, and are difficult for patients to participate in. Recent technological advances and a dynamic policy landscape in the United States have created a fertile ground for the use of real-world data (RWD) to improve current methods of clinical evidence generation. Sources of RWD include electronic health records, insurance claims, patient registries, and digital health solutions outside of conventional clinical trials. A definition focused on the original intent of data collected at the point of care can distinguish RWD from conventional clinical trial data. When the intent of data collection at the point of care is research, RWD can be generated using experimental designs similar to those employed in conventional clinical trials, but with several advantages that include gains in efficient execution of studies with an appropriate balance between internal and external validity. RWD can support active pharmacovigilance, insights into the natural history of disease, and the development of external control arms. Prospective collection of RWD can enable evidence generation based on pragmatic clinical trials (PCTs) that support randomized study designs and expand clinical research to the point of care. PCTs may help address the growing demands for access to experimental therapies while increasing patient participation in cancer clinical trials. Conducting valid real-world studies requires data quality assurance through auditable data abstraction methods and new incentives to drive electronic capture of clinically relevant data at the point of care.Keywords
This publication has 39 references indexed in Scilit:
- Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer TreatmentJAMA, 2017
- Randomized Trial Comparing a Web-Mediated Follow-up With Routine Surveillance in Lung Cancer PatientsJNCI Journal of the National Cancer Institute, 2017
- Accelerating development of scientific evidence for medical products within the existing US regulatory frameworkNature Reviews Drug Discovery, 2017
- From big data to smart data: FDA's INFORMED initiativeNature Reviews Drug Discovery, 2017
- Digital Pharmacovigilance and Disease Surveillance: Combining Traditional and Big-Data Systems for Better Public HealthThe Journal of Infectious Diseases, 2016
- Toward Enhanced Pharmacovigilance Using Patient-Generated Data on the InternetClinical Pharmacology & Therapeutics, 2014
- An agenda for UK clinical pharmacology: PharmacovigilanceBritish Journal of Clinical Pharmacology, 2012
- Launching HITECHNew England Journal of Medicine, 2010
- Pharmacovigilance: methods, recent developments and future perspectivesEuropean Journal of Clinical Pharmacology, 2008
- Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reportsPharmacoepidemiology and Drug Safety, 2001